Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000132276 | SCV000187360 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-04-11 | criteria provided, single submitter | clinical testing | The p.A353V variant (also known as c.1058C>T), located in coding exon 10 of the PMS2 gene, results from a C to T substitution at nucleotide position 1058. The alanine at codon 353 is replaced by valine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Color Diagnostics, |
RCV000132276 | SCV000686093 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-09-20 | criteria provided, single submitter | clinical testing | This missense variant replaces alanine with valine at codon 353 of the PMS2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with PMS2-related disorders in the literature. This variant has been identified in 6/251154 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Labcorp Genetics |
RCV000629818 | SCV000750774 | uncertain significance | Hereditary nonpolyposis colorectal neoplasms | 2024-11-05 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 353 of the PMS2 protein (p.Ala353Val). This variant is present in population databases (rs543676323, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with PMS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 142838). Invitae Evidence Modeling incorporating data from in vitro experimental studies (internal data) indicates that this missense variant is not expected to disrupt PMS2 function with a negative predictive value of 95%. RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (internal data). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genetic Services Laboratory, |
RCV001818331 | SCV002069438 | uncertain significance | not specified | 2018-08-22 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000132276 | SCV002529748 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-02-08 | criteria provided, single submitter | curation | |
Gene |
RCV002281059 | SCV002569822 | uncertain significance | not provided | 2022-08-29 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 22290698, 11574484) |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001818331 | SCV002572165 | uncertain significance | not specified | 2022-08-19 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003462041 | SCV004205481 | uncertain significance | Lynch syndrome 4 | 2023-08-21 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV003998139 | SCV004839853 | uncertain significance | Lynch syndrome | 2023-10-06 | criteria provided, single submitter | clinical testing | This missense variant replaces alanine with valine at codon 353 of the PMS2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with PMS2-related disorders in the literature. This variant has been identified in 6/251154 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |